Nuvilex Inc. Affiliate Readies for Future Clinical Trials

Nuvilex Inc. Affiliate Readies for Future Clinical Trials

On May 10, 2013, Goldman Small Cap Research published an Article on Nuvilex, Inc. (OTCQB – NVLX).  For your convenience, a copy of the article can be found below.
Please see previous NVLX reports for relevant disclosures and disclaimer.

Nuvilex Inc. Affiliate Readies for Future Clinical Trials

According to a recent article in the highly regarded bioscience publication BioSpectrum Asia, Nuvilex Inc. (OTCQB – NVLX) affiliate Austrianova Singapore has taken steps vital to the Company’s goal of engaging in late-stage pancreatic cancer clinical trials. The Firm has established a research cell bank in concert with a leading contract research organization in Europe.  This cell bank will be used for the production of the Company’s live cell encapsulation offering, which has demonstrated significant ability to activate the cancer pro-drug ifosfamide in close proximity to the pancreatic cancer itself, thus resulting in a high degree of antitumor efficacy with  a low toxicity profile for the anticancer drug, in Phase II clinical trials.  The encapsulation platform’s effectiveness remains high even when the chemotherapeutic agent dosage is reduced by two-thirds, thus enhancing the patients’ quality of life as well.
With the launch of the cell bank, the Company has embarked on the first step necessary to ensure the availability of the large number of encapsulated cells that will be required for the commencement of a Phase III pancreatic cancer clinical trial, along with other possible trials that may be done in the future that use the cell encapsulation as part of treatment regimens to treat various forms of cancer.  The bank will essentially “grow” the live cells required for encapsulation in which the cells are enclosed in small (about the size of the head of a pin) cellulose-based “beads” or capsules that are then implanted in the pancreatic patient’s body near the cancer itself.  In this way the effects of the anticancer drug are optimized right where it is needed most.  Furthermore, the encapsulated cancer-drug-activating cells stay near the tumor site, where they were implanted, during cancer drug administration and for months, even years after, all the time remaining alive and active and able to activate additional anticancer drug if it were to be used.  Given that a Phase III pancreatic cancer trial or even Phase I/II trials to treat other forms of cancer would require a large number of cells due to number of trial subjects, Nuvilex (OTCQB – NVLX) stands prepared to produce the requisite number of cells necessary for such  trials.
The Company plans that the late-phase clinical trial in patients with advanced, inoperable, pancreatic cancer will be “first in line” to use the cells produced from the cell bank.   The remarkable performance of the Company’s encapsulated cell technology platform for pancreatic cancer has been cited in a number of medical journals and publications including the highly regarded Lancet and Cancer Therapy.  Plus, data from the aforementioned pancreatic trial studies was recently featured in a review of promising cancer therapies by leading international scientists from the International Society for Cell and Gene Therapy.
Validation from these well-regarded third-party sources and the launch of the cell bank indicate that Nuvilex (OTCQB – NVLX) is on the cusp of making significant progress toward the initiation of various cancer clinical trials, most importantly the late-stage pancreatic cancer trial, given the devastating and deadly nature of that disease.
This article was paid for by a third party.